Massachusetts Financial Services CO Eiger Bio Pharmaceuticals, Inc. Transaction History

Massachusetts Financial Services CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$5.12 - $8.19 $160,368 - $256,527	-31,322 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$6.68 - $9.1 $2,752 - $3,749	-412 Reduced 1.3%	31,322 $209,000
Q2 2021 Aug 13, 2021	BUY	$7.82 - $9.23 $2,127 - $2,510	272 Added 0.86%	31,734 $270,000
Q1 2021 May 13, 2021	SELL	$8.44 - $12.66 $31,472 - $47,209	-3,729 Reduced 10.6%	31,462 $278,000
Q4 2020 Feb 12, 2021	SELL	$7.98 - $12.29 $2,824 - $4,350	-354 Reduced 1.0%	35,191 $432,000

Q3 2020 Nov 12, 2020	BUY	$7.96 - $12.42 $282,938 - $441,468	35,545 New	35,545 $289,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.